In this podcast from the virtual 2020 ESMO World Congress on Gastrointestinal Cancer, Dr. Zev Wainberg discusses emerging data from the phase 1/2 trial of first-line liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin for pancreatic ductal adenocarcinoma (PDAC).

Published on the AUA website and developed by a panel of experts from these three groups as well as representation from the American Society of Clinical Oncology (ASCO) and a patient advocate, 38 recommendations are listed across the care continuum of advanced disease.

According to the FDA, Phesgo — the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf – is initially used in combination with chemotherapy and then can be administered subcutaneously at home by a health care professional after completion of chemotherapy.

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC.

The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens.